🔗 Share this article

As the US proceeds with unprecedented changes to its immunization schedules, a particular individual has emerged in a surprising turn: Dr. Tracy Beth Høeg, a Danish American physician and public health researcher who first made her name by questioning COVID-19 shots during the pandemic and has concentrated on alleged fatalities after COVID-19 vaccination in her short time at the Food and Drug Administration.

Proposed Changes to Childhood Vaccine Schedule

Agency leaders were set to unveil sweeping revisions to the pediatric immunization program recently, bringing the US with the Danish immunization schedule, according to reports – a substantial departure that would place the US out of alignment with much of the global community with insufficient data for benefit. The planned update has been pushed back until the new year.

Rather than the director of the vaccine center, Høeg is listed to speak at the meeting. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the division this year.

A New Direction at the Regulatory Body

Høeg's temporary position could signify a tighter collaboration between the drug and biologics divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it signals a renewed priority upon dismantling previously authorized vaccines at the FDA.

Høeg has often pushed for ending specific pediatric immunization guidelines in the US so as to align more in line with Denmark, a society with comprehensive healthcare and a number of inhabitants about the size of the state of Wisconsin.

To date comments, she has kept her attention on vaccination policy – usually the purview of Prasad, chief of the FDA’s CBER – instead of pharmaceutical oversight.

Doubts Over Background

Høeg has no obvious background in drug development, approval processes or management, which has been typical for past heads of the biologics center. She has worked at the FDA as a top consultant to the agency head and the vaccine center since spring.

“It seems she lacks to have the necessary background” for running the CDER, stated Jonathan Howard. “She’s never run a clinical trial. She is not versed in running a sizeable institution. She lacks background in industry regulation.”

Past heads of the center would “grasp legal statutes and the science of pharmaceutical innovation”, said Dr. Janet Woodcock. “Frankly, she lacks the kind of background that former directors who headed the center have had.”

The drug center has an enormous portfolio at the FDA, she stated.

“The public just pays attention on the innovative therapies, but the generic program clears a multitude of off-brand pharmaceuticals. There is also a biologic copycat branch, non-prescription drug unit and other areas, and all of those have to be supervised,” Woodcock noted. “The area you don’t keep your eye on, that is the part that I always told people is going to bite you.”

Furthermore, a substantial management component to the role, which manages in excess of 5,000 staff members. “It is a massive management job, if you do it right,” the former official concluded.

Official Statement and Controversial Initiatives

In response to questions about Dr. Høeg's fitness for the role and whether this appointment indicates more teamwork among agency officials on vaccines, a spokesperson said that the “inquiries are based on flawed presumptions”.

“Her resume aligns with the responsibilities of her job,” the spokesperson said, noting the period Dr. Høeg spent counseling the FDA commissioner on “pharmaceutical safety and approval science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s recently launched priority voucher program, a contentious rapid drug-approval program that allegedly worried her former heads. “By what process are these medications being picked for this voucher program? Who takes the decisions?” Dr. Howard asked. “There is a lot of confidentiality going on at the FDA right now.”

In general, he said, “the FDA appears to be shifting towards less stringent regulations of all drugs, except for shots.”

Public History on Immunizations

With vaccines, Høeg has a more documented, if troubling, track record, some experts have noted. She released a research paper using unverified public submissions to assess the incidence of myocarditis after Covid vaccination. She counseled the Florida surgeon general Joseph Ladapo, who allegedly have changed statistics to suggest Covid vaccines are riskier than they are.

Part of her “desired changes” for the incoming administration encompassed revising regulations for new vaccines and discontinuing “non-essential” immunizations, she said following the vote on a podcast. At the agency, Dr. Høeg has allegedly suggested preventing adolescent males from getting COVID-19 vaccines.

“She’s an thorough ideologue who begins with her preconceived notions and tailors the evidence to retrofit the evidence in a very misleading, fraudulent fashion,” Howard argued.

Gaining Influence and a “Push for Payback”

Høeg became part of other dissenters, {like|